Lilly drug slows Alzheimer's progression by 35% in trial
An experimental Alzheimer's drug developed by Eli Lilly slowed cognitive decline by 35% in a closely watched late-stage trial, the company said, raising hopes for another treatment for the brain disorder that slowly destroys memory.
Comentarios
Publicar un comentario
Leave a comment. Thanks!
Comentarios de Facebook